

This newsletter summarises final decisions from HTA bodies around the world from January 2024.

These decisions are categorised into one of four groups.

- Decisions of HTA bodies are categorised according to the type of intervention into Pharmacological, Non-Pharmacological and Diagnostic.
- Statements from HTA bodies in the form of guidelines on the management of a disease using specific interventions are included under Other Guidance.

Click on the category you are interested in to jump to that section

[Pharmacological Technologies](#)

[Non-pharmacological Technologies](#)

[Diagnostic Tests](#)

[Other Guidance](#)

Within each section the reports have been grouped according to clinical speciality. On the section contents page, there are shortcuts to each clinical speciality and specific report. All tiles are hyperlinked to the report file or to the HTA website.

Here we list a key for the decisions made by the HTA bodies for the reports listed in this newsletter:



The reporting document states that the technology has been approved.



The reporting document states that the technology has not been approved.



The report was terminated, additional details are provided under the icon.



The report was excluded because it is covered by another HTA body in that country.



This is where documentation cannot be translated or it is unclear on the reporting outcome.



This entry includes a note from the report relating to the technology.




This is for reports that do not report a decision but summarises the evidence for the technology.

Pharmacological Technologies



Cancer

- Atezolizumab - Finland
- Axicabtagene ciloleucel - Scotland
- Belantamab mafodotin - Scotland
- Epcoritamab - Germany
- Epcoritamab - Wales
- Nivolumab - Germany
- Nivolumab - Finland
- Nivolumab - Finland
- Nivolumab/Relatimab - Wales
- Pembrolizumab - Scotland
- Talazoparib - Wales



Eye

- Ranibizumab - Australia



Infection

- Amoxicillin-clavulanic acid/Xilmac - Finland
- Recombinant respiratory syncytial virus pre-fusion F protein - Australia



Genetic/Metabolic

- Burosumab - Scotland
- Exagamglogene autotemcel - France
- Pegunigalsidase alfa - Germany
- Setmelanotide - Scotland

Other

- Ustekinumab - Australia

Non-pharmacological Technologies



Cancer

- Additional surgery - England



Musculoskeletal

- Intraoperative CT - South Korea
- Prosthesis with plasma spray coating - Argentina

Other

- Autologous platelet rich fibrin therapy - South Korea



Pregnancy


- Caesarean section - England

Diagnostic Technologies



Cancer

- Stockholm3 test - Norway



Gastrointestinal

- Exhaled air test - Argentina



Genitourinary

- Flexible single-use ureteroscope - Argentina



Mental health

- Seoul Cognitive Status Test - South Korea



Genetic/Metabolic

- von Willebrand Factor Collagen Binding Activity immunoassay - South Korea



Pregnancy

- Respectful Maternity Care - United States

Other Guidance



Cancer

- [Gene expression profiling tests - Ireland](#)
- [Leucovorin - Canada](#)
- [Screening for colorectal cancer - Canada](#)



Genitourinary

- [Arteriovenous Fistulas - Canada](#)
- [Ketorolac - Canada](#)



Infection

- [Enhanced inactivated influenza vaccines - Ireland](#)
- [Self-sampling - Spain](#)



Mental health

- [Ketamine - Canada](#)



Musculoskeletal

- [Fracture sonography - Germany](#)

Other

- [Buprenorphine - Canada](#)
- [Bupropion, cytisine, nicotine and varenicline - Germany](#)
- [Cannabis and other plant-based treatments - United States](#)
- [Ketamine - Canada](#)

Respiratory

- [Biologic Drugs - Canada](#)
- [Endobronchial Valves - Canada](#)



Surgery

- [Hernia Support Garments - Canada](#)



Pharmacological Technologies



Cancer

Finland



Atezolizumab

Adjuvant therapy for non-small cell lung cancer with >50% PD-L1.

FINCCHTA



Population:
Unknown

January 2024

Scotland



Axicabtagene ciloleucel

For relapsed or refractory follicular lymphoma.

SMC2646



Population:
Adult

15 January 2024

Scotland



Belantamab mafodotin

For progressive, refractory multiple myeloma.

SMC2597



Population:
Adult

15 January 2024

Germany



Epcoritamab

For relapsed or refractory diffuse large B-cell lymphoma.

IQWiG G23-27



Population:
Adult

08 January 2024

Orphan Drug Status

Pharmacological Technologies



Cancer

Wales



Epcoritamab

For relapsed or refractory diffuse large B-cell lymphoma.

AWTTC



Excluded due to NICE appraisal ID4045

Population:
Unknown

15 January 2024

Germany



Nivolumab

Population:
Adult and Adolescent
≥12 years old

22 December 2023

For stage IIB or IIC melanoma.

IQWiG A23-94



Approved for adults, not approved for adolescents ≥12 years old

Finland



Nivolumab

For untreated metastatic urothelial cancer.

FINCCHTA



Population:
Unknown

January 2024

Finland



Nivolumab

For operable non-small cell lung cancer with >1% tumour PD-L1.

FINCCHTA



Population:
Unknown

January 2024

Pharmacological Technologies



Cancer

Wales



Nivolumab/
Relatimab

Population:
Unknown

03 January 2024



For untreated unresectable or metastatic melanoma.

AWTTC



Excluded due to NICE appraisal ID1688

Scotland



Pembrolizumab

Population:
Adult

15 January 2024



For advanced/recurrent endometrial carcinoma and refractory unresectable/metastatic colorectal, gastric, small intestine, or biliary cancer.

SMC2589



Wales



Talazoparib

Population:
Adult

19 January 2024



For HER2-negative locally advanced or metastatic breast cancer with BRCA1/2 mutations.

AWTTC



Excluded due to NICE appraisal ID1342

Pharmacological Technologies



Eye



Infection

Australia



Ranibizumab

For neovascular (wet) AMD; DME; PDR; choroidal neovascularisation; CNV secondary to pathologic myopia; DME secondary to RVO.

TGA



Not recommended for preterm infants

08 January 2024

Finland



Amoxicillin-clavulanic acid/
Xilmac

Population:
Unknown

January 2024

For prophylaxis and treatment of infection.

FINCCHTA



Population:
Adult

Australia



Recombinant respiratory syncytial virus pre-fusion F protein

Population:
Adult
≥60 years old

22 January 2024

To prevent lower respiratory tract disease caused by RSV.

TGA



Pharmacological Technologies



Genetic/Metabolic

Scotland



Burosumab

For X-linked hypophosphataemia with bone disease.

SMC2588



Population:
Children and Adolescent
1 to 17 years old

15 January 2024

France



Exagamglogene autotemcel

For transfusion-dependent β -thalassemia in patients eligible for HSCT.

HAS - AP262



Population:
Adult, Adolescent and Children
12 to 35 years old

24 January 2024

Germany



Pegunigalsidase alfa

For Fabry disease.

IQWiG A23-95



Population:
Adult

22 December 2023

Scotland



Setmelanotide

For obesity and control of hunger in Bardet-Biedl syndrome (BBS).

SMC2647




Population:
Adult and Children ≥ 12 years old

15 January 2024

Pharmacological Technologies

Other



Skin

Australia



Ustekinumab

Population:
Adult and Children

30 January 2024

For plaque psoriasis,
psoriatic arthritis,
Crohn's disease and
ulcerative colitis.

TGA



Germany



Sirolimus

Population:
Adult, Adolescent
and Children
≥6 years old

19 December 2023

For facial angiofibroma
in tuberous sclerosis.

IQWiG G23-28



Orphan Drug Status

Non-pharmacological Technologies



Cancer



Musculoskeletal

England



For breast cancer after breast-conserving surgery.

NICE - NG101



Updated recommendations

16 January 2024

South Korea



Intraoperative CT

Population: Unknown

January 2024



For navigational spine surgery.

NECA



Argentina



Prosthesis with plasma spray coating

Population: Unknown

January 2024



For knee arthroplasty.

IECS



Non-pharmacological Technologies

Other



Pregnancy

South Korea



For wound healing.

NECA



Autologous platelet
rich fibrin therapy

Population:
Adult

January 2024

England



Caesarean section

Population:
Adult

30 January 2024

In women and pregnant
people.

NICE - NG192




New and updated
recommendations

Diagnostic Technologies



Cancer



Gastrointestinal

Norway



For prostate cancer risk assessment.

Stockholm3 test

Argentina



For bacterial overgrowth syndrome.

Exhaled air test

Population:
Unknown

FHI

Population:
Unknown

IECS



10 January 2024

January 2024

Diagnostic Technologies



Genitourinary

Argentina




Flexible single-use
ureteroscope

Population:
Unknown

January 2024

For urological
pathologies.

IECS



Musculoskeletal

South Korea



Seoul Cognitive
Status Test

Population:
Adult
50 to 90 years old

January 2024

For diagnosis of
cognitive impairment.

NECA



Diagnostic Technologies



Genetic/Metabolic



Pregnancy

South Korea



von Willebrand
Factor Collagen
Binding Activity
immunoassay

For von Willebrand
disease type 2.

NECA



Population:
Unknown

January 2024

United States



Respectful Maternity
Care

In women and pregnant
people.

AHRQ - CER269

Population:
Adult



January 2024

Other Guidance



Cancer

Ireland



Gene expression
profiling tests

For early-stage invasive
breast cancer.

HIQA



Population:
Unknown

22 January 2024

Canada



Leucovorin

Dosing for
gastrointestinal cancer.

CADTH RC1518-000



Population:
Unknown

09 January 2024

Canada



Screening for
colorectal cancer

Review of risk of
colorectal cancer in
under 50s.

CADTH RD0069-000



Population:
Adult
<50 years old

08 January 2024

Other Guidance



Genitourinary



Infection

Canada



For haemodialysis
access.

CADTH RC1519-000



Arteriovenous
Fistulas

Population:
Adult

08 January 2024

Ireland



Enhanced
inactivated influenza
vaccines

Population:
Adult
≥65 years old

25 January 2024

For prevention of
influenza.

HIQA



Canada



For renal colic.

CADTH RC1525-000



Ketorolac

Population:
Unknown

18 January 2024

Spain



Self-sampling

Population:
Adult

January 2024

For human papilloma
virus assessment.

EUSKADI



Other Guidance



Mental Health

Canada



Ketamine


For treatment-resistant depression or post-traumatic stress disorder.

CADTH RC1522-000



Population:
Adult

23 January 2024



Musculoskeletal

Germany



Fracture sonography

For suspected fracture of a long bone of the upper extremities.

IWQiG D22-02




Population:
Children

15 December 2023

Other Guidance

Other


Canada



Buprenorphine


Population:
Unknown

30 January 2024



For opioid use disorder.

CADTH RE0051-000




Germany



Bupropion, cytisine, nicotine and varenicline


Population:
Unknown

08 January 2024



For tobacco use cessation.

IQWiG A22-34




United States



Cannabis and other plant-based treatments


Population:
Adult

January 2024



For chronic pain.

AHRQ




Canada



Ketamine


Population:
Adult

09 January 2024



For chronic non-cancer pain.

CADTH RC1521-000



Other Guidance



Respiratory

Canada



Biologic Drugs

For severe asthma.

CADTH RE0047-000

Population:
Adult and Children



30 January 2024



Surgery

Canada



Hernia Support Garments

For parastomal hernia following ostomy.

CADTH RC1520-000

Population:
Unknown



08 January 2024

Canada



Endobronchial Valves

For severe emphysema.

CADTH RC1524-000

Population:
Adult



18 January 2024

About Us

Crystallise provides an innovative approach to identify and synthesise information, using AI to automate processes and assist our experts to produce deliverables that provide real value to clients.

Our team of researchers, medical writers and copy-editors deliver strategically-relevant and comprehensive written reports as well as visually informative summary slide decks, to suit internal business development, market access, journal publication and health technology assessment submissions.

REVIEWS

Systematic Literature Reviews
Global Value Dossiers
Narrative Reviews
Rapid Reviews
Targeted Reviews

HEALTH ECONOMICS

Return on Investment
Network Meta-Analysis
Budgetary Impact Analysis
Cost-effectiveness Analysis

ACTUARIAL

Risk Management
Pricing & Reserving

MODELLING

Mortality and Morbidity Modelling
Synthetic Sample Generation
Infectious Disease Modelling

[To provide feedback on the HTAngel newsletter, click here.](#)

[To unsubscribe, click here.](#)

Registered address

17 High Street,
Stanford-le-Hope,
Essex, SS17 0HD
+44 (0)1375 517878

Company No: 7980921

Data Protection Act Registration Number: Z3363643

Websites:

www.crystallise.com

www.heoro.com

www.evidencemapper.co.uk